30 closest matches · ranked by relevance
Graft Versus Host Disease · Ophthalmologic Complications
Primary: Change in Patient-reported Symptoms Measured by the 8-point Lee Eye Subscale — 75.4; 63.2; 61.8; 56.3 units on a scale — p=0.01
Graft Versus Host Disease · Systemic Scleroderma
Primary: Significant Clinical Response — 9; 10 participants
Graft-versus-host-disease (GVHD)
Primary: Percentage of Participants With Complete and Partial Responses in Skin and/or Joint — 49 percentage of participants
Sclerotic Graft Versus Host Disease · Imatinib Mesylate
Primary: Percent Change in Absolute Range of Motion (ROM) From Baseline to 6 Months — 94; 35; 16; 21 Percent change from baseline
Chronic Myeloproliferative Disorders · Graft Versus Host Disease · Leukemia
Primary: Number of Patients That Develop Ocular GVHD While on Study in the Two Arms (Ocular Cyclosporine (Restasis) vs. Placebo) — 9; 8 participants — p=>0.99
Ocular GVHD
Primary: Ocular Burning Sensation, Ocular Discharge, Ocular Redness, Ocular Itching, Foreign Body Sensation — 3.50; 2.23; 0.16; 0.26 units on a scale — p=0.0019
Chronic Ocular Graft-versus-host Disease
Primary: Modified SANDE Questionnaire - Frequency, Change From Baseline — -22.00; -4.59 score on a scale — p=0.0197
Dry Eyes
Primary: Progression of Dry Eye Severity — 15; 12 patients with increased dry eye severity
Scleritis
Primary: Number of Participants Who Experience at Least 2-step Reduction or Reduction to Grade 0 of Scleral Inflammation in the Study Eye According to the National Eye Institute…
GVHD · Ocular Rosacea · Dry Eye Syndrome
Primary: Number of Participants Who Responded to Intense Pulsed Light (IPL) — 5; 2 participants
Chronic Graft Versus Host Disease
Primary: Number of Participants With an Overall Response at Week 28 — 20; 14 Participants — p=0.373
Scleritis
Primary: Number of Participants With at Least a 2-step Reduction or Reduction to Grade 0 in Scleral Inflammation in the Study Eye (or Eyes), According to the National Eye…
Systemic Scleroderma · Severe Systemic Sclerosis
Primary: Event-free Survival (EFS) — 1 Participants
SYSTEMIC SCLERODERMA
Primary: Time to Treatment Failure — 0; 8 participants
Chronic GVHD
Primary: Proportion of Participants With Treatment Success — 33; 35; 33; 37 Participants — p=0.63
Systemic Scleroderma
Primary: EFS of Patients Undergoing Transplant — 15 participants
Oral Chronic Graft vs Host Disease
Primary: Percentage of Participants With a Response as Assessed by the 273-point Oral Mucositis Rating Scale (OMRS) Who Received Topical Clobetasol 0.05% Oral Rinse for Oral…
Graft vs Host Disease
Primary: Clinical Activity — 4; 4 participants
Acute Graft Versus Host Disease
Primary: The Percentage of Patients Who Progress Within 28 Days of Initiation of Etanercept Treatment — 29 percentage of patients
Graft Versus Host Disease
Primary: Number of Participants Experiencing Treatment Success — 8 Participants
Graft Versus Host Disease
Primary: Day 56 Treatment Success — 57; 72; 43; 47 percentage of participants
Oral Chronic Graft-versus-host Disease
Primary: The Clinical Efficacy of Topical Steroid and Topical Tacrolimus Therapies for the Treatment of Oral cGHVD. — 15; 3; 11; 2 participants
Acute Leukemia · Chronic Myelogenous Leukemia · Myelodysplasia
Primary: Percentage of Participants With GVHD/Relapse or Progression-free Survival (GRFS) — 35.5; 27.2; 44.1 percentage of participants
Chronic Graft-versus-host Disease
Primary: Change From Baseline (Visit 1) of Total Corneal Fluorescein Staining Score at 12 Weeks. — -4.2; -6.2; -2.1 units on a scale
Scleroderma · Interstitial Lung Disease
Primary: Forced Vital Capacity (FVC), as a Percent of the Age, Height, Gender, and Ethnicity Adjusted Predicted Value — 66.52; 66.52; 66.22; 67.03 FVC %-pred — p=0.24
Scleroderma
Primary: Improvement in the Modified Rodnan Skin Score. — 46.75 percent improvement from baseline
Chronic Graft Versus Host Disease
Primary: Overall Response Rate After a 15 Week Course of Bortezomib Plus Prednisone in Patients With cGVHD — 2; 14; 1; 2 participants
Scleritis · Orbital Disease
Primary: Reduction of Medications — 5; 4 participants
Ectropion · Skin Neoplasms
Primary: Graft Size Change — 10 percent change in graft
Rheumatologic Disease
Primary: Flow Mediated Dilatation (FMD)-Diameter of Artery — 3.79; 3.78 mm